scholarly journals Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss

2010 ◽  
Vol 41 (2) ◽  
pp. 385-393 ◽  
Author(s):  
M. Preter ◽  
S. H. Lee ◽  
E. Petkova ◽  
M. Vannucci ◽  
S. Kim ◽  
...  

BackgroundThe expanded suffocation false alarm theory (SFA) hypothesizes that dysfunction in endogenous opioidergic regulation increases sensitivity to CO2, separation distress and panic attacks. In panic disorder (PD) patients, both spontaneous clinical panics and lactate-induced panics markedly increase tidal volume (TV), whereas normals have a lesser effect, possibly due to their intact endogenous opioid system. We hypothesized that impairing the opioidergic system by naloxone could make normal controls parallel PD patients' response when lactate challenged. Whether actual separations and losses during childhood (childhood parental loss, CPL) affected naloxone-induced respiratory contrasts was explored. Subjective panic-like symptoms were analyzed although pilot work indicated that the subjective aspect of anxious panic was not well modeled by this specific protocol.MethodRandomized cross-over sequences of intravenous naloxone (2 mg/kg) followed by lactate (10 mg/kg), or saline followed by lactate, were given to 25 volunteers. Respiratory physiology was objectively recorded by the LifeShirt. Subjective symptomatology was also recorded.ResultsImpairment of the endogenous opioid system by naloxone accentuates TV and symptomatic response to lactate. This interaction is substantially lessened by CPL.ConclusionsOpioidergic dysregulation may underlie respiratory pathophysiology and suffocation sensitivity in PD. Comparing specific anti-panic medications with ineffective anti-panic agents (e.g. propranolol) can test the specificity of the naloxone+lactate model. A screen for putative anti-panic agents and a new pharmacotherapeutic approach are suggested. Heuristically, the experimental unveiling of the endogenous opioid system impairing effects of CPL and separation in normal adults opens a new experimental, investigatory area.

Analgesia ◽  
1995 ◽  
Vol 1 (4) ◽  
pp. 809-812
Author(s):  
O. Valverde ◽  
M.-C. Fournié-Zaluski ◽  
B. P. Roques ◽  
R. Maldonado

2014 ◽  
Vol 125 (2) ◽  
pp. 117-124 ◽  
Author(s):  
Shiroh Kishioka ◽  
Norikazu Kiguchi ◽  
Yuka Kobayashi ◽  
Fumihiro Saika

2021 ◽  
Vol 89 (9) ◽  
pp. S385
Author(s):  
Cheng Jiang ◽  
Ralph DiLeone ◽  
Christopher Pittenger ◽  
Ronald Duman

1988 ◽  
Vol 105 (2) ◽  
pp. 162-164 ◽  
Author(s):  
G. N. Kryzhanovskii ◽  
L. P. Bakuleva ◽  
N. L. Luzina ◽  
V. A. Vinogradov ◽  
K. N. Yarygin ◽  
...  

2007 ◽  
Vol 52 (3) ◽  
pp. 931-948 ◽  
Author(s):  
Pilar Sánchez-Cardoso ◽  
Alejandro Higuera-Matas ◽  
Sonsoles Martín ◽  
Nuria del Olmo ◽  
Miguel Miguéns ◽  
...  

1997 ◽  
Vol 273 (3) ◽  
pp. R956-R959 ◽  
Author(s):  
M. Bertolucci ◽  
C. Perego ◽  
M. G. De Simoni

The central endogenous opioid system is involved in the modulation of interleukin (IL)-6, an inflammatory cytokine that plays a major role in the acute phase response. The present study evaluates whether specific opioid receptor subtypes are selectively involved in this immunomodulatory action. IL-1 beta was administered either intracerebroventricularly or intraperitoneally at the dose of 400 ng to rats pretreated with the mu-antagonist beta-funaltrexamine, the delta-antagonist naltrindole, or the kappa-antagonist nor-binaltorphimine, each at the doses of 1, 10, and 100 micrograms/rat intracerebroventricularly. Serum IL-6 levels were measured 2 h later. The results show that mu-receptor blockade increases, whereas delta-receptor blockade decreases IL-6 induction, suggesting that the fine tuning exerted by opioids on the immune system may be achieved through a balance of opposing effects. Moreover the three antagonists affect IL-6 induction by central and peripheral IL-1 beta with a similar pattern, indicating that the brain endogenous opioid system plays a general role in the regulation of this cytokine.


2014 ◽  
Vol 39 (13) ◽  
pp. 2974-2988 ◽  
Author(s):  
Javier Gutiérrez-Cuesta ◽  
Aurelijus Burokas ◽  
Samantha Mancino ◽  
Sami Kummer ◽  
Elena Martín-García ◽  
...  

2020 ◽  
Author(s):  
Agata Twardowska ◽  
Jakub Fichna ◽  
Agata Binienda

Enkefalinazy, należące do rodziny metaloproteaz zależnych od jonów cynku pełnią ważną rolę w regulacji aktywności endogennego układu opioidowego (ang. endogenous opioid system, EOS). Inhibitory enkefalinaz pozwalają na zwiększenie stężenia wybranych endogennych peptydów opioidowych, co znalazło zastosowanie w lecznictwie. Pierwszym lekiem opartym na tym mechanizmie działania był racekadotryl, wykazujący działanie przeciwbiegunkowe. W przeciwieństwie do innych leków wpływających na aktywność EOS, stosowanie racekadotrylu wiąże się z niższym prawdopodobieństwem wystąpienia efektów ubocznych, co może być kluczowym kryterium przy doborze leczenia u pacjentów z przewlekłymi chorobami jelit, którym towarzyszy biegunka. Dominujący udział EOS w modulacji informacji nocyceptywnej stwarza również perspektywy do zastosowania inhibitorów enkefalinaz w leczeniu bólu. W pracy omówiono zastosowanie inhibitorów enkefalinaz w chorobach układu pokarmowego, takich jak zespół jelita drażliwego oraz nieswoiste choroby zapalne jelit.


Sign in / Sign up

Export Citation Format

Share Document